Institutional members access full text with Ovid®

Share this article on:

Longitudinal Racial/Ethnic Disparities in Antimanic Medication Use in Bipolar-I Disorder

Busch, Alisa B. MD, MS*†‡; Huskamp, Haiden A. PhD‡; Neelon, Brian PhD‡; Manning, Tim BA‡; Normand, Sharon-Lise T. PhD‡§; McGuire, Thomas G. PhD‡

doi: 10.1097/MLR.0b013e3181adcc4f
Original Article

Objective: To examine racial/ethnic longitudinal disparities in antimanic medication use among adults with bipolar-I disorder.

Methods: Observational study using administrative data from Florida's Medicaid program, July 1997 to June 2005, for enrollees diagnosed with bipolar-I disorder (N = 13,497 persons; 126,413 person-quarters). We examined the likelihood of receiving one of the following during a given quarter: (1) any antimanic agent (antipsychotic or mood stabilizer) or none, and (2) mood stabilizers, antipsychotic monotherapy, or neither. Binary and multinomial logistic regression models predicted the association between race/ethnicity and prescription fills, adjusting for clinical and demographic characteristics. Cohort indicators for year that the enrollee met study criteria were included to account for cohort effects.

Results: Averaging over all cohorts and quarters, compared with whites, blacks had lower odds of filling any antimanic and mood stabilizer prescriptions specifically (40%–49% and 47%–63%, respectively), but similar odds of filling prescriptions for antipsychotic monotherapy. After Bonferroni adjustment, compared with whites, there were no statistically significant disparities for Hispanics in filling prescriptions for any, or specific antimanic medications.

Conclusions: Rates of antimanic medication use were low regardless of race/ethnicity. However, we found disparities in antimanic medication use for blacks compared with whites and these disparities persisted over time. We found no Hispanic-white disparities. Quality improvement efforts should focus on all individuals with bipolar disorder, but particular attention should be paid to understanding disparities in medication use for blacks.

From the *Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts; †Department of Psychiatry, and ‡Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts; and §Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.

Supported from the National Institute of Mental Health K01MH071714 (Dr. Busch), K01MH66109 (Dr. Huskamp), P50 MH073469 (Dr. McGuire), and R01-MH61434 (Drs. McGuire, Neelon, and Normand, and Mr. Manning), the Robert Wood Johnson Foundation (RWJF) Investigator Award in Health Policy Research (Dr. Huskamp), †the MacArthur Foundation Research Network on Mandated Community Treatment (Dr. McGuire), and the National Center for Minority Health and Disparities 20 MD000537 (Dr. McGuire).

Reprints: Alisa B. Busch, MD, MS, McLean Hospital, Division of Alcohol and Drug Abuse, Proctor Building, Room 305, 115 Mill St, Belmont, MA 02478. E-mail: abusch@hcp.med.harvard.edu.

© 2009 Lippincott Williams & Wilkins, Inc.